Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Related Citations for PubMed (Select 24815673)

1.

Psychomotor symptoms and treatment outcomes of ziprasidone monotherapy in patients with major depressive disorder: a 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial.

Jeon HJ, Fava M, Mischoulon D, Baer L, Clain A, Doorley J, DiPierro M, Cardoos A, Papakostas GI.

Int Clin Psychopharmacol. 2014 Nov;29(6):332-8. doi: 10.1097/YIC.0000000000000039.

PMID:
24815673
2.

Efficacy of ziprasidone monotherapy in patients with anxious depression: A 12-week, randomized, double-blind, placebo-controlled, sequential-parallel comparison trial.

Heo JY, Jeon HJ, Fava M, Mischoulon D, Baer L, Clain A, Doorley J, Pisoni A, Papakostas GI.

J Psychiatr Res. 2015 Mar;62:56-61. doi: 10.1016/j.jpsychires.2015.01.007. Epub 2015 Jan 26.

PMID:
25659187
3.

A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder.

Papakostas GI, Vitolo OV, Ishak WW, Rapaport MH, Zajecka JM, Kinrys G, Mischoulon D, Lipkin SH, Hails KA, Abrams J, Ward SG, Meisner A, Schoenfeld DA, Shelton RC, Winokur A, Okasha MS, Bari MA, Fava M.

J Clin Psychiatry. 2012 Dec;73(12):1541-7. doi: 10.4088/JCP.12m07670.

PMID:
23290327
4.
5.
6.

A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.

Hellerstein DJ, Stewart JW, McGrath PJ, Deliyannides DA, Batchelder ST, Black SR, Withers A, O'Shea D, Chen Y.

J Clin Psychiatry. 2012 Jul;73(7):984-91. doi: 10.4088/JCP.11m07230.

PMID:
22901348
7.

Repetitive transcranial magnetic stimulation for the treatment of major depressive disorder: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2004;4(7):1-98. Epub 2004 Jun 1.

8.

Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial.

Mischoulon D, Witte J, Levy M, Papakostas GI, Pet LR, Hsieh WH, Pencina MJ, Ward S, Pollack MH, Fava M.

J Clin Psychiatry. 2012 Mar;73(3):353-7. doi: 10.4088/JCP.10m06541. Epub 2011 Sep 20.

PMID:
21939613
9.

A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder.

Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME.

J Clin Psychiatry. 2012 Jul;73(7):953-9. doi: 10.4088/JCP.11m07470.

PMID:
22901346
10.

Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial.

Keck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K; Ziprasidone in Mania Study Group.

Am J Psychiatry. 2003 Apr;160(4):741-8.

PMID:
12668364
11.

Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study.

Magid M, Reichenberg JS, Poth PE, Robertson HT, LaViolette AK, Kruger TH, Wollmer MA.

J Clin Psychiatry. 2014 Aug;75(8):837-44. doi: 10.4088/JCP.13m08845.

PMID:
24910934
12.
13.

Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.

Khin NA, Chen YF, Yang Y, Yang P, Laughren TP.

J Clin Psychiatry. 2011 Apr;72(4):464-72. doi: 10.4088/JCP.10m06191. Erratum in: J Clin Psychiatry. 2011 Jun;72(6):874.

PMID:
21527123
14.

Psychometric properties of the Chinese versions of the Quick Inventory of Depressive Symptomatology - Clinician Rating (C-QIDS-C) and Self-Report (C-QIDS-SR).

Liu J, Xiang YT, Wang G, Zhu XZ, Ungvari GS, Kilbourne AM, Lai KY, Zhong BL, Zhang L, Zhang Q, Zou YC, Xiao L, Zhao Q, Li Y, Wu J, Zhang GF, Chiu HF.

J Affect Disord. 2013 May;147(1-3):421-4. doi: 10.1016/j.jad.2012.08.035. Epub 2012 Sep 18.

PMID:
22995944
15.

A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state.

Patkar A, Gilmer W, Pae CU, Vöhringer PA, Ziffra M, Pirok E, Mulligan M, Filkowski MM, Whitham EA, Holtzman NS, Thommi SB, Logvinenko T, Loebel A, Masand P, Ghaemi SN.

PLoS One. 2012;7(4):e34757. doi: 10.1371/journal.pone.0034757. Epub 2012 Apr 24.

16.

Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.

Sachs GS, Ice KS, Chappell PB, Schwartz JH, Gurtovaya O, Vanderburg DG, Kasuba B.

J Clin Psychiatry. 2011 Oct;72(10):1413-22. doi: 10.4088/JCP.09m05934.

PMID:
21672493
17.

The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.

Sung SC, Haley CL, Wisniewski SR, Fava M, Nierenberg AA, Warden D, Morris DW, Kurian BT, Trivedi MH, Rush AJ; CO-MED Study Team.

J Clin Psychiatry. 2012 Jul;73(7):967-76. doi: 10.4088/JCP.11m07043. Epub 2012 May 29.

PMID:
22687487
18.

Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?

Lombardo I, Sachs G, Kolluri S, Kremer C, Yang R.

J Clin Psychopharmacol. 2012 Aug;32(4):470-8. doi: 10.1097/JCP.0b013e31825ccde5.

PMID:
22722504
19.

Efficacy of extended release quetiapine fumarate monotherapy in elderly patients with major depressive disorder: secondary analyses in subgroups of patients according to baseline anxiety, sleep disturbance, and pain levels.

Montgomery SA, Altamura AC, Katila H, Datto C, Szamosi J, Eriksson H.

Int Clin Psychopharmacol. 2014 Mar;29(2):93-105. doi: 10.1097/YIC.0000000000000007.

PMID:
24162081
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk